163 related articles for article (PubMed ID: 25862911)
1. Assessment of circulating serum DNA integrity in colorectal cancer patients.
Yörüker EE; Özgür E; Keskin M; Dalay N; Holdenrieder S; Gezer U
Anticancer Res; 2015 Apr; 35(4):2435-40. PubMed ID: 25862911
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients.
Bedin C; Enzo MV; Del Bianco P; Pucciarelli S; Nitti D; Agostini M
Int J Cancer; 2017 Apr; 140(8):1888-1898. PubMed ID: 27943272
[TBL] [Abstract][Full Text] [Related]
3. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy.
Agostini M; Pucciarelli S; Enzo MV; Del Bianco P; Briarava M; Bedin C; Maretto I; Friso ML; Lonardi S; Mescoli C; Toppan P; Urso E; Nitti D
Ann Surg Oncol; 2011 Sep; 18(9):2461-8. PubMed ID: 21416156
[TBL] [Abstract][Full Text] [Related]
4. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats.
Umetani N; Kim J; Hiramatsu S; Reber HA; Hines OJ; Bilchik AJ; Hoon DS
Clin Chem; 2006 Jun; 52(6):1062-9. PubMed ID: 16723681
[TBL] [Abstract][Full Text] [Related]
5. Free circulating DNA as possible tumour marker in colorectal cancer.
Boni L; Cassinotti E; Canziani M; Dionigi G; Rovera F; Dionigi R
Surg Oncol; 2007 Dec; 16 Suppl 1():S29-31. PubMed ID: 18024018
[TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of plasma cell-free DNA and its DNA integrity in patients with metastatic prostate cancer using ALU sequence.
Fawzy A; Sweify KM; El-Fayoumy HM; Nofal N
J Egypt Natl Canc Inst; 2016 Dec; 28(4):235-242. PubMed ID: 27634416
[TBL] [Abstract][Full Text] [Related]
7. Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients.
Agostini M; Enzo MV; Bedin C; Belardinelli V; Goldin E; Del Bianco P; Maschietto E; D'Angelo E; Izzi L; Saccani A; Zavagno G; Nitti D
Cancer Biomark; 2012; 11(2-3):89-98. PubMed ID: 23011155
[TBL] [Abstract][Full Text] [Related]
8. Serum DNA integrity index as a potential molecular biomarker in endometrial cancer.
Vizza E; Corrado G; De Angeli M; Carosi M; Mancini E; Baiocco E; Chiofalo B; Patrizi L; Zampa A; Piaggio G; Cicchillitti L
J Exp Clin Cancer Res; 2018 Jan; 37(1):16. PubMed ID: 29382392
[TBL] [Abstract][Full Text] [Related]
9. Increased DNA integrity in colorectal cancer.
Leszinski G; Lehner J; Gezer U; Holdenrieder S
In Vivo; 2014; 28(3):299-303. PubMed ID: 24815830
[TBL] [Abstract][Full Text] [Related]
10. LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer.
Nagai Y; Sunami E; Yamamoto Y; Hata K; Okada S; Murono K; Yasuda K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Kawai K; Nozawa H; Ishihara S; Hoon DS; Watanabe T
Oncotarget; 2017 Feb; 8(7):11906-11916. PubMed ID: 28060757
[TBL] [Abstract][Full Text] [Related]
11. Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer.
Spindler KG
Acta Oncol; 2017 Jan; 56(1):7-16. PubMed ID: 28010185
[TBL] [Abstract][Full Text] [Related]
12. Cell-free circulating DNA: Diagnostic value in patients with renal cell cancer.
Hauser S; Zahalka T; Ellinger J; Fechner G; Heukamp LC; VON Ruecker A; Müller SC; Bastian PJ
Anticancer Res; 2010 Jul; 30(7):2785-9. PubMed ID: 20683013
[TBL] [Abstract][Full Text] [Related]
13. Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and prostate cancers.
Arko-Boham B; Aryee NA; Blay RM; Owusu EDA; Tagoe EA; Doris Shackie ES; Debrah AB; Adu-Aryee NA
Cancer Genet; 2019 Jun; 235-236():65-71. PubMed ID: 31105051
[TBL] [Abstract][Full Text] [Related]
14. Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing.
Medina Diaz I; Nocon A; Mehnert DH; Fredebohm J; Diehl F; Holtrup F
PLoS One; 2016; 11(11):e0166354. PubMed ID: 27832189
[TBL] [Abstract][Full Text] [Related]
15. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
[TBL] [Abstract][Full Text] [Related]
16. Different primers for diagnosing circulating cell-free DNA of colorectal cancer.
Shi H; Li Q; Liao J; Bai L; Wu S; Xie J; He G
Transl Cancer Res; 2020 May; 9(5):3435-3442. PubMed ID: 35117709
[TBL] [Abstract][Full Text] [Related]
17. Increased Free Circulating DNA Integrity Index as a Serum Biomarker in Patients with Colorectal Carcinoma.
El-Gayar D; El-Abd N; Hassan N; Ali R
Asian Pac J Cancer Prev; 2016; 17(3):939-44. PubMed ID: 27039817
[TBL] [Abstract][Full Text] [Related]
18. Utility of cell-free tumour DNA for post-surgical follow-up of colorectal cancer patients.
Levy M; Benesova L; Lipska L; Belsanova B; Minarikova P; Veprekova G; Zavoral M; Minarik M
Anticancer Res; 2012 May; 32(5):1621-6. PubMed ID: 22593440
[TBL] [Abstract][Full Text] [Related]
19. Alu-based cell-free DNA: a potential complementary biomarker for diagnosis of colorectal cancer.
Qi J; Qian C; Shi W; Wu X; Jing R; Zhang L; Wang Z; Ju S
Clin Biochem; 2013 Jan; 46(1-2):64-9. PubMed ID: 22975639
[TBL] [Abstract][Full Text] [Related]
20. A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening.
Zou H; Harrington JJ; Klatt KK; Ahlquist DA
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1115-9. PubMed ID: 16775168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
